We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.

We evaluated trending and awareness for MCC in oncologists and dermatologists over the past decade and found spikes align with treatments.

We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.